Using Cardiac Targeting Peptide to deliver miRNA for molecular reversal of heart failure

使用心脏靶向肽传递 miRNA 以分子逆转心力衰竭

• 批准号: 10481720
• 负责人: G IAN GALLICANO
• 金额: $ 28.47万
• 依托单位: VIVASC THERAPEUTICS INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-13 至 2024-07-12
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10481720
• 关键词: Address; Adult; Affect; Amino Acids; Angiotensin II; Angiotensin Receptor; Angiotensin-Converting Enzyme Inhibitors; Animal Model; Apoptosis; Arrhythmia; Biodistribution; Biological Assay; Biotin; CRISPR/Cas technology; Cardiac; Cardiac Myocytes; Cell membrane; Cell physiology; Cells; Cicatrix; Complex; Coupling; Data; Development; Disease; Dose; Endothelial Cells; Endothelium; Environment; Enzymes; Epinephrine; Event; Exposure to; Family; Fibroblasts; Gene Activation; Gene Expression; Genes; Goals; Health; Heart; Heart Hypertrophy; Heart failure; Human; In Vitro; Individual; Inflammation; Injections; Intravenous; Investigational Drugs; Kidney; Knock-out; Knowledge; Label; Left; Legal patent; Letters; Link; Liver; Logic; Longevity; Luciferases; MicroRNAs; Molecular; Morbidity - disease rate; Morphology; Mus; Myocardium; Myofibroblast; Nucleic Acids; Nucleotides; Organ; Pathologic; Pathway interactions; Patients; Pattern; Peptides; Persons; Pharmaceutical Preparations; Pharmacotherapy; Phase; Phase I Clinical Trials; Phenotype; Physiological; Physiology; Plant Roots; Prevalence; Process; Protein Isoforms; Publishing; Quality of life; Radioisotopes; Recovery; Relaxation; Role; Safety; Signaling Molecule; Small Business Technology Transfer Research; Streptavidin; Stress; TXN gene; Technology; Testing; Therapeutic; Tissues; Transcriptional Activation; Treatment Failure; Western Blotting; Wild Type Mouse; Work; calmodulin-dependent protein kinase II; cardiogenesis; cell injury; clinical development; commercial application; commercialization; cost; cyanine dye 5; disulfide bond; improved; in vivo; in vivo evaluation; in vivo imaging system; induced pluripotent stem cell; mortality; mouse model; novel; overexpression; pre-clinical; side effect; symptom treatment; synthetic peptide; targeted treatment; technological innovation; therapeutic miRNA; therapeutically effective; time use; uptake; vector

PROJECT SUMMARY/ABSTRACT Heart failure (HF) is a common disease with well-documented morbidity and mortality that affects approximately 23 million people globally, including 6 million in the US. Current HF medications such as Angiotensin Converting Enzyme (ACE) Inhibitors or Angiotensin Receptor Blockers (ARBs) treat the symptoms of HF versus the root cause of the disease, which includes stressed myocardium that leads to hypertrophic cardiomyocytes and endothelial inflammation. CaMKIIδ is a signaling molecule that regulates cellular pathways involved in excitation‑contraction coupling and relaxation events in the heart and transcriptional activation of genes related to cardiac hypertrophy, inflammation, and arrhythmias. If left uncorrected, CaMKIIδ‑regulated changes culminate in a dysfunctional myocardium and HF. The goal of this STTR Phase I project is to address this root cause of HF by delivering miRNA to cardiomyocytes to down-regulate the over-expression and/or activation of CaMKIIδ because this may allow damaged cardiomyocytes to regain normal function. To achieve this goal, a specific miRNA will be selected that effectively inhibits the expression of CaMKIIδ in vivo. This miRNA will then be conjugated to the proprietary cell penetrating peptide, Cardiac Targeting Peptide (CTP), developed by Vivasc Therapeutics. This will create a CTP-miRNA conjugate that will deliver this nucleotide specifically and directly to cardiomyocytes. CTP is a novel, synthetic peptide that has transduced (i) normal mouse hearts in vivo (peak uptake at 15 minutes after injection), (ii) explanted human heart tissue, and (iii) human derived iPSC beating cardiomyocytes. CTP has demonstrated robust transduction of normal cardiomyocytes while sparing myofibroblasts, endothelial cells, and fibroblasts present in scar tissue. To date, CTP conjugates have transduced cardiomyocytes carrying intact cargoes as diverse as radioisotopes, nucleic acids, other peptides, and conjugates as large as the biotin-streptavidin complex. The team’s preliminary data has shown that CTP is fully capable of carrying miRNA in a similar manner. The hypothesis is that CTP-miRNA will deliver miRNA to cardiomyocytes that are over expressing CaMKIIδ, thereby allowing damaged cardiomyocytes to regain normal function. The aims are: 1) deliver specific miRNAs to the hearts of HF mouse models to demonstrate their efficacy in reversing HF physiology and 2) test the in vivo biodistribution of CTP-miRNA using a dual-labeled CTP-miRNA. Phase II plans include conducting studies of optimized CTP-miRNA in larger animal models of HF and IND- enabling studies to support an Investigational New Drug (IND) submission for approval of a Phase 1 clinical trial. Upon approval, this treatment could potentially be prescribed to HF patients with cardiac hypertrophy, inflammation, and arrhythmias.

项目总结/摘要 心力衰竭（HF）是一种常见疾病，有充分的发病率和死亡率记录， 全球约有2300万人，其中美国有600万人。目前的HF药物，如 血管紧张素转换酶（ACE）抑制剂或血管紧张素受体阻滞剂（ARB）治疗症状 HF与疾病的根本原因，包括导致肥大的应激心肌， 心肌细胞和内皮炎症。 CaMKIIδ是一种信号分子，调节参与兴奋-收缩偶联的细胞途径 以及心脏中的舒张事件和与心脏肥大相关的基因的转录激活， 炎症和心律失常。如果不加以纠正，CaMKIIδ调节的变化最终会导致功能障碍， 心肌和HF。本STTR第一阶段项目的目标是通过提供 miRNA对心肌细胞下调CaMKIIδ的过度表达和/或激活， 可以使受损的心肌细胞恢复正常功能。 为了实现这一目标，将选择一种特异性的miRNA，其有效地抑制细胞中CaMKIIδ的表达。 vivo.然后将该miRNA与专利的细胞穿透肽，心脏靶向肽缀合 (CTP)由Vivasc Therapeutics开发。这将产生一种CTP-miRNA缀合物， 核苷酸特异性且直接作用于心肌细胞。CTP是一种新型的合成肽，其已转导（i） 体内正常小鼠心脏（注射后15分钟的峰值摄取），（ii）经处理的人心脏组织，和 (iii)人来源的iPSC搏动心肌细胞。CTP已经证明了正常细胞的稳健转导。 心肌细胞，同时保留瘢痕组织中存在的肌成纤维细胞、内皮细胞和成纤维细胞。到目前为止， CTP缀合物具有转导的心肌细胞，所述心肌细胞携带与放射性同位素、核酸、细胞因子和细胞因子一样多样的完整货物。 酸、其他肽和与生物素-链霉抗生物素蛋白复合物一样大的缀合物。团队的初步数据 已经表明CTP完全能够以类似的方式携带miRNA。 假设CTP-miRNA将递送miRNA至过度表达CaMKIIδ的心肌细胞， 从而使受损的心肌细胞恢复正常功能。其目的是：1）递送特异性miRNAs 以证明它们在逆转HF生理学方面的功效，以及2）测试它们在HF小鼠模型中的作用。 使用双标记的CTP-miRNA的CTP-miRNA的体内生物分布。 II期计划包括在较大的HF和IND动物模型中进行优化的CTP-miRNA的研究。 使研究能够支持研究性新药（IND）提交，以获得1期临床批准 审判一旦获得批准，这种治疗可能会被用于心脏肥大的HF患者， 炎症和心律失常。